# A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07474727/  
OnCo record `nct07474727` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FLOT, Bevacizumab, Cetuximab in colorectal cancer, run by Multitude Therapeutics Inc., now recruiting.

## Summary

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07474727 by Multitude Therapeutics Inc., with 180 participants planned, started 2026-04-29 and due to reach its primary completion in 2027-09-30. Interventions recorded: AMT-676, 5-FU, Leucovorin, Bevacizumab, Cetuximab. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07474727
- Phase: 2
- Setting: An Phase II Study Evaluating the Safety and Efficacy of AMT-676 in Combination With 5-fluorouracil, Leucovorin, Bevacizumab (or Cetuximab) in Participants of Advanced Colorectal Cancer
- Sponsor: Multitude Therapeutics Inc.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07474727: https://clinicaltrials.gov/study/NCT07474727

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/)
- companies: [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07474727.json